Adolfo Suarez, MD
Family Medicine · Commerce, GANPI 1104910157
Payments from drug & device makers
Across 367 payments — averaging $20.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Paratek Pharmaceuticals, Inc.$1K
- Novo Nordisk$1K
- AstraZeneca$754
- Supernus Pharmaceuticals, Inc.$725
- Corium, LLC$432
- Otsuka America Pharmaceutical, Inc.$368
- plus $3K from 28 others
What the payments were for
- Consulting fees$90012%
- Food & beverage$6,67288%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Paratek Pharmaceuticals, Inc. | 19 | $1,212 |
| Novo Nordisk | 60 | $1,084 |
| AstraZeneca | 20 | $754 |
| Supernus Pharmaceuticals, Inc. | 34 | $725 |
| Corium, LLC | 34 | $432 |
| Otsuka America Pharmaceutical, Inc. | 19 | $368 |
| Lilly USA, LLC | 22 | $341 |
| Boehringer Ingelheim | 15 | $255 |
| Sanofi-aventis U.S. LLC | 12 | $215 |
| Merck | 14 | $214 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 19 | $195 |
| Pfizer | 10 | $195 |
| Amgen | 11 | $183 |
| Johnson & Johnson | 11 | $181 |
| GSK | 10 | $176 |
| Abbott | 8 | $168 |
| Novartis | 8 | $145 |
| AbbVie(2 entities) | 7 | $121 |
| Amarin Pharma, Inc. | 6 | $95 |
| Kowa Pharmaceuticals America, Inc. | 4 | $65 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $57 |
| Ironshore Pharmaceuticals Inc. | 3 | $53 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $51 |
| Idorsia Pharmaceuticals US Inc | 2 | $42 |
| Exact Sciences | 2 | $41 |
| Lundbeck LLC | 2 | $40 |
| Mylan Specialty L.p. | 2 | $27 |
| Dexcom, Inc. | 1 | $24 |
| Lucid Diagnostics Inc. | 1 | $21 |
| Genentech USA, Inc. | 1 | $21 |
| Teva Pharmaceuticals USA, Inc. | 1 | $20 |
| Eisai Inc. | 1 | $20 |
| Biohaven Pharmaceuticals, Inc. | 1 | $19 |
| Currax Pharmaceuticals LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,572 in reported general payments places this provider in the 90th percentile of 3,111 family medicine providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RybelsusSemaglutide | 76 | $83,845 |
| FarxigaDapagliflozin Propanediol | 84 | $63,320 |
| JanuviaSitagliptin Phosphate | 52 | $58,985 |
| EliquisApixaban | 95 | $54,413 |
| JardianceEmpagliflozin | 49 | $46,702 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 50 | $38,741 |
| TrulicityDulaglutide | 31 | $34,935 |
| MounjaroTirzepatide | 26 | $30,608 |
| RexultiBrexpiprazole | 24 | $26,204 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 22 | $23,317 |
| LinzessLinaclotide | 33 | $20,806 |
| XareltoRivaroxaban | 21 | $17,058 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 18 | $15,434 |
| OzempicSemaglutide | 15 | $14,459 |
| EntrestoSacubitril/Valsartan | 15 | $12,796 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskRybelsus, Ozempic | $1,084 | $98,30491 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $754 | $78,754102 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $341 | $65,54357 claims |
| MerckJanuvia | $214 | $58,98552 claims |
| Boehringer IngelheimJardiance, Tradjenta | $255 | $58,13670 claims |
| PfizerEliquis | $195 | $54,41395 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $176 | $43,89463 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $368 | $26,20424 claims |
| AbbVieLinzess | $121 | $20,80633 claims |
| Johnson & JohnsonXarelto | $181 | $17,05821 claims |
| NovartisEntresto | $145 | $12,79615 claims |
| Idorsia Pharmaceuticals US IncQuviviq | $42 | $6,08312 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,111 family medicine providers in Georgia.
Other family medicine in Commerce
- Joseph SurberColumbus$16.6M
- Angela RitterGainesville$15.8M
- Jeffrey KingsleyColumbus$8.1M
- Christopher OldfieldSavannah$6.4M
- Darrell MurrayAtlanta$3.9M
- Ben ThomasAtlanta$3.2M
- Debbie HaginsSavannah$2.1M
- Aziz PiraniLilburn$2.1M
- Nadia CameronAtlanta$2.1M
- John LentzSnellville$1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.